Literature DB >> 22431140

TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle.

Luisa Piva1, Bruno F Gavassini, Luca Bello, Marina Fanin, Gianni Soraru, Andrea Barp, Mario Ermani, Corrado Angelini, Eric P Hoffman, Elena Pegoraro.   

Abstract

A polymorphism (rs28357094) in the promoter region of the SPP1 gene coding for osteopontin (OPN) is a strong determinant of disease severity in Duchenne muscular dystrophy (DMD). The rare G allele of rs28357094 alters gene promoter function and reduces mRNA expression in transfected HeLa cells. To dissect the molecular mechanisms of increased disease severity associated with the G allele, we characterized SPP1 mRNA and protein in DMD muscle biopsies of patients with defined rs28357094 genotype. We did not find significant differences in osteopontin mRNA or protein expression between patients carrying the T (ancestral allele) or TG/GG genotypes at rs28357094. The G allele was significantly associated with reduced CD4(+) and CD68(+) cells on patient muscle biopsy. We also quantified transforming growth factor-β (TGFB) and TGFB receptor-2 (TGFBR2) mRNA in DMD muscle biopsies, given the ability of TGFB and TGFBR2 to activate SPP1 promoter region and their role in DMD pathogenesis. The amount of TGFB and TGFBR2 mRNA did not predict the amount of SPP1 mRNA or protein, while a polymorphism in the TGFBR2 gene (rs4522809) was found to be a strong predictor of SPP1 mRNA level. Our findings suggest that OPN mediates inflammatory changes in DMD and that TGFB signalling has a role in the complex regulation of osteopontin expression.
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431140      PMCID: PMC4121062          DOI: 10.1002/path.4026

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  31 in total

1.  TGFbeta and BMP-2 activation of the OPN promoter: roles of smad- and hox-binding elements.

Authors:  T G Hullinger; Q Pan; H L Viswanathan; M J Somerman
Journal:  Exp Cell Res       Date:  2001-01-01       Impact factor: 3.905

2.  Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy.

Authors:  Y-W Chen; K Nagaraju; M Bakay; O McIntyre; R Rawat; R Shi; E P Hoffman
Journal:  Neurology       Date:  2005-08-10       Impact factor: 9.910

3.  Dystrophin: the protein product of the Duchenne muscular dystrophy locus.

Authors:  E P Hoffman; R H Brown; L M Kunkel
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

4.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

5.  Osteopontin expression in coculture of differentiating rat fetal skeletal fibroblasts and myoblasts.

Authors:  Renata O Pereira; Simone N Carvalho; Ana Carolina Stumbo; Carlos A B Rodrigues; Luis Critóvão Porto; Anibal S Moura; Laís Carvalho
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jan-Feb       Impact factor: 2.416

6.  A genetic polymorphism in transforming growth factor beta receptor-2 is associated with serum osteopontin.

Authors:  E Biros; P Clancy; P E Norman; J Golledge
Journal:  Int J Immunogenet       Date:  2009-08       Impact factor: 1.466

7.  Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.

Authors:  Priyanka Sharma; Santosh Kumar; Gopal C Kundu
Journal:  Mol Cancer       Date:  2010-07-07       Impact factor: 27.401

8.  Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis.

Authors:  Miranda D Grounds; Jo Torrisi
Journal:  FASEB J       Date:  2004-04       Impact factor: 5.191

9.  Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease.

Authors:  M M Shull; I Ormsby; A B Kier; S Pawlowski; R J Diebold; M Yin; R Allen; C Sidman; G Proetzel; D Calvin
Journal:  Nature       Date:  1992-10-22       Impact factor: 49.962

10.  Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis.

Authors:  Yong Li; William Foster; Bridget M Deasy; Yisheng Chan; Victor Prisk; Ying Tang; James Cummins; Johnny Huard
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

View more
  15 in total

1.  Genetic Modifiers for Neuromuscular Diseases.

Authors:  Kay-Marie Lamar; Elizabeth M McNally
Journal:  J Neuromuscul Dis       Date:  2014

Review 2.  Outside in: The matrix as a modifier of muscular dystrophy.

Authors:  Mattia Quattrocelli; Melissa J Spencer; Elizabeth M McNally
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-12-21       Impact factor: 4.739

3.  Osteopontin, inflammation and myogenesis: influencing regeneration, fibrosis and size of skeletal muscle.

Authors:  Charles N Pagel; Dimuthu K Wasgewatte Wijesinghe; Neda Taghavi Esfandouni; Eleanor J Mackie
Journal:  J Cell Commun Signal       Date:  2013-12-08       Impact factor: 5.782

Review 4.  Modifying muscular dystrophy through transforming growth factor-β.

Authors:  Ermelinda Ceco; Elizabeth M McNally
Journal:  FEBS J       Date:  2013-04-24       Impact factor: 5.542

Review 5.  Modifier genes and their effect on Duchenne muscular dystrophy.

Authors:  Andy H Vo; Elizabeth M McNally
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

6.  Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype.

Authors:  Natassia M Vieira; Ingegerd Elvers; Matthew S Alexander; Yuri B Moreira; Alal Eran; Juliana P Gomes; Jamie L Marshall; Elinor K Karlsson; Sergio Verjovski-Almeida; Kerstin Lindblad-Toh; Louis M Kunkel; Mayana Zatz
Journal:  Cell       Date:  2015-11-12       Impact factor: 41.582

7.  Assessing the translational landscape of myogenic differentiation by ribosome profiling.

Authors:  Eleonora de Klerk; Ivo F A C Fokkema; Klaske A M H Thiadens; Jelle J Goeman; Magnus Palmblad; Johan T den Dunnen; Marieke von Lindern; Peter A C 't Hoen
Journal:  Nucleic Acids Res       Date:  2015-04-14       Impact factor: 16.971

8.  Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.

Authors:  Luca Bello; Akanchha Kesari; Heather Gordish-Dressman; Avital Cnaan; Lauren P Morgenroth; Jaya Punetha; Tina Duong; Erik K Henricson; Elena Pegoraro; Craig M McDonald; Eric P Hoffman
Journal:  Ann Neurol       Date:  2015-03-13       Impact factor: 10.422

Review 9.  Dystrophin induced cognitive impairment: mechanisms, models and therapeutic strategies.

Authors:  Akshay Anand; Rahul Tyagi; Manju Mohanty; Manoj Goyal; K Ranil D De Silva; Nalaka Wijekoon
Journal:  Ann Neurosci       Date:  2015-04

10.  Eccentric muscle challenge shows osteopontin polymorphism modulation of muscle damage.

Authors:  Whitney L Barfield; Kitipong Uaesoontrachoon; Chung-Sheih Wu; Stephen Lin; Yue Chen; Paul C Wang; Yasmine Kanaan; Vernon Bond; Eric P Hoffman
Journal:  Hum Mol Genet       Date:  2014-03-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.